Search

Your search keyword '"Annis, James"' showing total 57 results

Search Constraints

Start Over You searched for: Author "Annis, James" Remove constraint Author: "Annis, James" Publisher american association for cancer research (aacr) Remove constraint Publisher: american association for cancer research (aacr)
57 results on '"Annis, James"'

Search Results

1. Supplementary Figure 1 from PPP2R2C Loss Promotes Castration-Resistance and Is Associated with Increased Prostate Cancer-Specific Mortality

2. Supplementary Figure Legends from PPP2R2C Loss Promotes Castration-Resistance and Is Associated with Increased Prostate Cancer-Specific Mortality

3. Supplementary Figure 2 from PPP2R2C Loss Promotes Castration-Resistance and Is Associated with Increased Prostate Cancer-Specific Mortality

4. Data from PPP2R2C Loss Promotes Castration-Resistance and Is Associated with Increased Prostate Cancer-Specific Mortality

5. Supplementary Figure 1 from PPP2R2C Loss Promotes Castration-Resistance and Is Associated with Increased Prostate Cancer-Specific Mortality

6. Supplementary Figure Legends from PPP2R2C Loss Promotes Castration-Resistance and Is Associated with Increased Prostate Cancer-Specific Mortality

7. Supplementary Tables 1-3 from PPP2R2C Loss Promotes Castration-Resistance and Is Associated with Increased Prostate Cancer-Specific Mortality

8. Supplementary Tables 1-3 from PPP2R2C Loss Promotes Castration-Resistance and Is Associated with Increased Prostate Cancer-Specific Mortality

9. Supplementary Figure 2 from PPP2R2C Loss Promotes Castration-Resistance and Is Associated with Increased Prostate Cancer-Specific Mortality

10. Data from PPP2R2C Loss Promotes Castration-Resistance and Is Associated with Increased Prostate Cancer-Specific Mortality

11. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

12. Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

13. Supplementary Tables S18-20 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer

14. Supplementary Table Legends from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer

15. Supplementary Table S21 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer

16. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

17. Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

18. Supplementary Figure S1 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer

19. Supplementary Table Legends from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer

20. Supplementary Figure S4 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer

21. Supplementary Tables S1-8 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer

22. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

23. Supplementary Figure S3 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer

24. Supplementary Figure S2 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer

25. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

26. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

27. Supplementary Tables S1-8 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer

28. Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

29. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

30. Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

31. Supplementary Figure S2 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer

32. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

33. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

34. Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

35. Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

36. Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

37. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

38. Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

39. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

40. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

41. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

42. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

43. Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

44. Supplementary Table S21 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer

45. Supplementary Figure S1 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer

46. Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

47. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

48. Supplementary Figure S4 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer

49. Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

50. Supplementary Figure S3 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer

Catalog

Books, media, physical & digital resources